RESULTS: Of the 1725 eligible patients, 736 (42.7%) had sufficient data to calculate APV. Those without APV data had a greater proportion of dMET and a faster time to dMET, as well as poorer pathologic features than those who had sufficient APV data. dMET was observed in 11% of patients. We observed a significantly faster time to dMET among the rapid APV group (p<0.001). In multivariable analysis, rapid APV was predictive of over a two-fold increased odds in dMET (HOR ¼ 2.08, p ¼ 0.0215).
INTRODUCTION AND OBJECTIVES:
The current pre-treatment nomograms for prostate cancer were developed and validated based on a patient population that primarily consisted of men with low or intermediate risk prostate cancer. This study aims to develop a preoperative nomogram that predicts for metastasis from a contemporary cohort of men with NCCN high (HR) or very high risk (VHR) prostate cancer.
METHODS: We identified 1,241 men from 2005 to 2015 with NCCN HR or VHR prostate cancer from two large academic medical centers primarily treated with radical prostatectomy. The cohort was divided into training (n¼620) and validation (n¼621) cohorts. The primary endpoint of analysis was mets. Multivariable Cox proportional hazards regression analysis was used to model characteristics and outcomes in the training cohort. Predictive accuracy was assessed using the time-dependent area under the receiver operating characteristic curve (AUC) in the validation cohort.
RESULTS: 123 men (64 training and 59 validation) developed metastasis. The overall metatasis-free probability was 86.5% (95% CI 83.7%-89.4%) at 5-years. Predictive nomograms including age, ethnicity, PSA, Gleason grade, clinical stage, and the number of positive cores with Gleason 8-10 disease were developed. The AUC for the model was 0.75. In comparison, the MSKCC preoperative nomogram and CAPRA nomogram had AUCs of 0.66 and 0.67 respectively.
CONCLUSIONS: Individualized risk assessment is imperative for optimal decision making for both disease management and appropriate clinical trial design. The nomogram described here, created from a population composed of HR/VHR men, has greater predictive accuracy of mets up to 5 years after radical prostatectomy than those previously established on cohorts of primarily low and intermediate risk men. Thus, this nomogram may be a more suitable approach for predicting mets in men with HR or VHR disease. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e169
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MP14-20 PREDICTORS OF EARLY DISEASE SPECIFIC MORTALITY AMONG PATIENTS WITH PROSTATE ADENOCARCINOMA BONE METASTASIS AT DIAGNOSIS
Zachary Klaassen*, Thenappan Chandrasekar, Hanan Goldberg, Robert J. Hamilton, Neil E. Fleshner, Girish S. Kulkarni, Toronto, Canada INTRODUCTION AND OBJECTIVES: Two recent randomized trials have suggested a survival benefit for patients with high volume metastatic prostate cancer (PCa) that initially receive chemotherapy. However, there is a paucity of data at the population-level characterizing which men presenting with bone metastatic disease are at highest risk for PCa-specific mortality (PCSM). The purpose of this study was to assess the demographic and clinicopathologic factors among patients with PCa bone metastasis at diagnosis and identify predictors of PCSM.
METHODS: Patients with prostate adenocarcinoma were identified between 2010-2013 from the SEER database (n¼200,616). Among this group, 8,040 men presented with bone metastasis, forming the study cohort. Descriptive statistics were used to compare demographic and clinicopathologic variables between patients experiencing PCSM and those that were alive/died of other causes. A Fine and Gray 0 s sub-distribution competing risks model was performed to generate hazards ratios (HR) for the identification of predictors of PCSM.
RESULTS: There were 2,497 men (31.1%) experiencing PCSM and 5,543 men (68.9%) without PCSM (n¼643 dead of other causes; n¼4,900 alive) over a median follow-up of 35 months 
MP15-01 CAN THE USE OF NARROW-BAND IMAGING (NBI) REDUCE PERSISTENT BLADDER CANCER RATE DURING WHITE-LIGHT CLASSIC TRANS-URETHRAL RESECTION OF TUMOR (WLCTURBT)? A PRELIMINARY SINGLE-CENTER EXPERIENCE IN A LARGE CASE SERIES.
Cristina Falavolti*, Barbara Cristina Gentile, Gabriella Mirabile, Paola Tariciotti, Luca Albanesi, Giorgio Rizzo, Maurizio Buscarini, Rome, Italy INTRODUCTION AND OBJECTIVES: Transurethral resection of bladder tumors is the mainstay approach in bladder cancer diagnosis and treatment. Nevertheless, persistent tumor lesion is present in 33-76% of patients after WLcTURBT and a tumor stage change is reported in about 40% of patients. The aim of this study was to evaluate the probability to detect persistent high-risk bladder cancer using NBI after an initial WLcTURBT METHODS: From June 2010 to April 2012, 797 patients (423 males and 374 females) affected by primary, recurrent or suspicious bladder lesions, underwent WLcTURBT. We performed NBI resection of every lesion margins and bed of resection during the same surgery session. Each fragment was separately analyzed. A logistic regression model was used to evaluate the correlation between persistent bladder tumor during repeat NBI resection and bladder cancer risk factors (stage, dimension and focality). The statistical analysis were conducted using Statistical Package for Social Science version 19 RESULTS: Overall, 512 patients were diagnosed with bladder cancer. We identified 1572 bladder lesions of which 1066 (67.8%) were bladder neoplasms after WLcTURBT. Bladder tumors features are showed in table 1. We found 195 (18.2%) persistent pT1 or pCIS tumors after NBI resection (p< 0.05). Of those, 119 lesions (11.1%) were already high-risk tumors (pT1 or pCIS) after the initial WLcTURBT. In 140 lesions (13.1%) we found residual pT1 tumors (49 on margins and 91 on bed of resection) and 55 lesions (5.1%) showed residual pCIS tumors (52 on margins and 3 on bed of resection). We observed a disease down-staging in 76 lesions (7.1%) who were diagnosed with pTa tumor after the initial WLcTURBT. Of those, 50 tumors resulted pT1 bladder cancer after repeat NBI resection and 26 pTa tumors were finally diagnosed with pCIS bladder cancer. Tumor focality was correlated with significant (p< 0.05) high-risk tumor persistence on lesion margins CONCLUSIONS: Bladder tumor persistence is significantly related to the endoscopic resection. NBI-TURBT represents a usefull procedure to detect residual high-risk tumors otherwise unidentifiable during WLcTURBT. Residual tumor rate in our study is 18%. Further studies are necessary to power this result
